TB R&D Weekly Update: Promoting Fixed-dose Combos for TB control

Monedero I, Caminero JA. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int J Tuberc Lung Dis. 2011 Apr;15(4):433-9.

In this week’s article, Monedero and Caminero conduct a critical review of research on the use of fixed-dosed combinations (FDCs) for tuberculosis with the conclusion that FDCs should continue to be promoted and recommended. FDCs combine two or more drugs in a regimen into one single fixed-dose which reduces the pill burden, which increases the chances that patients will adhere to treatment over longer periods.

The use of FDCs remains low in TB programs. The authors site the following reasons for utilizing a single pill instead of many separate pills:

1) Avoidance of drug selection by the patient which often leads to monotherapy,

2) Prevention of prescription errors,

3) Increased patient adherence due to reduced pill burden,

4) Improvements in drug handling and deliver and ultimately,

5) Improvements in TB outcomes and prevention of drug resistance.

A literature review was performed in 2010 and 15 articles were identified that were published between 1987 and 2009. The publications supported the hypothesis that FDCs have similar efficacy as use of single drugs together. Only one study addressed the relevancy of FDCs in preventing drug-resistance. It was noted that there were no published data on use of FDCs in the private sector. Based on their review, the authors felt that the FDCs should be promoted to increase low uptake, especially where DOTS is not fully implemented.

Additional R&D News:

New Way to Treat TB

Fiscal Year 2011 budget deal takes hit at PEPFAR and NIH

Voyageurs’ TB thrives among First Nations

Battle of the bugs

BioWatch: Sequella wins $3.8M to battle drug-resistant bacterium

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...